Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

A SU011248 Expanded Access Protocol For Systemic Therapy Of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation In Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248

The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive clinical benefit from treatment with SU011248 based on the judgment of the investigator.

Study Overview

• Status: Approved for marketing
• Conditions: Carcinoma, Renal Cell
• Intervention / Treatment: Drug: Sutent

Detailed Description

Given that an Expanded Access study does not meet the definition of a controlled clinical investigation, and as such, is not considered an applicable drug clinical trial per NIH, Basic Results for such studies are not required to be reported. Protocol A6181037 has been identified as an Expanded Access trial, and has been registered to ClinicalTrials.gov, however Basic Results will not be posted.

• Study Type: Expanded Access

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina, C1431FWO
    • Pfizer Investigational Site
  • Buenos Aires, Argentina, C1034ACO
    • Pfizer Investigational Site
  • Buenos Aires, Argentina, C1426ANZ
    • Pfizer Investigational Site
• Australia
  • New South Wales
    • Randwick, New South Wales, Australia, 2031
      • Pfizer Investigational Site
    • St Leonards, New South Wales, Australia, 2065
      • Pfizer Investigational Site
    • Westmead, New South Wales, Australia, 2145
      • Pfizer Investigational Site
  • Queensland
    • South Brisbane, Queensland, Australia, 4101
      • Pfizer Investigational Site
  • South Australia
    • Elizabeth Vale, South Australia, Australia, 5112
      • Pfizer Investigational Site
    • Woodville South, South Australia, Australia, 5011
      • Pfizer Investigational Site
  • Victoria
    • East Melbourne, Victoria, Australia, 3002
      • Pfizer Investigational Site
    • Heidelburg, Victoria, Australia, 3084
      • Pfizer Investigational Site
  • Western Australia
    • Perth, Western Australia, Australia, 6000
      • Pfizer Investigational Site
• Austria
  • Innsbruck, Austria, 6020
    • Pfizer Investigational Site
  • Wien, Austria, 1090
    • Pfizer Investigational Site
• Belgium
  • Bruxelles, Belgium, 1000
    • Pfizer Investigational Site
  • Bruxelles, Belgium, 1200
    • Pfizer Investigational Site
  • Gent, Belgium, 9000
    • Pfizer Investigational Site
  • Leuven, Belgium, 3000
    • Pfizer Investigational Site
  • Liege, Belgium, 4000
    • Pfizer Investigational Site
  • Wilrijk, Belgium, 2610
    • Pfizer Investigational Site
• Bosnia and Herzegovina
  • Sarajevo, Bosnia and Herzegovina, 71000
    • Pfizer Investigational Site
• Brazil
  • BA
    • Salvador, BA, Brazil, 41950-640
      • Pfizer Investigational Site
  • MG
    • Belo Horizonte, MG, Brazil, 30380-490
      • Pfizer Investigational Site
  • RJ
    • Rio de Janeiro, RJ, Brazil, 20230-130
      • Pfizer Investigational Site
    • Rio de Janeiro, RJ, Brazil, 20231-050
      • Pfizer Investigational Site
  • RS
    • Porto Alegre, RS, Brazil, 90610-000
      • Pfizer Investigational Site
  • Rio Grande do Sul
    • Porto Alegre, Rio Grande do Sul, Brazil, 90020-090
      • Pfizer Investigational Site
  • SP
    • Jau, SP, Brazil, 17210-120
      • Pfizer Investigational Site
    • Jaú, SP, Brazil, 17210-080
      • Pfizer Investigational Site
    • Jaú, SP, Brazil, 17210-120
      • Pfizer Investigational Site
    • São Paulo, SP, Brazil, 01509-900
      • Pfizer Investigational Site
    • São Paulo, SP, Brazil, 01308-050
      • Pfizer Investigational Site
    • São Paulo, SP, Brazil, 05651-000
      • Pfizer Investigational Site
• Bulgaria
  • Sofia, Bulgaria, 1756
    • Pfizer Investigational Site
  • Sofia, Bulgaria, 1504
    • Pfizer Investigational Site
• Canada
  • Quebec, Canada, G1R 2J6
    • Pfizer Investigational Site
  • Alberta
    • Calgary, Alberta, Canada, T2N 4N2
      • Pfizer Investigational Site
    • Edmonton, Alberta, Canada, T6G 1Z2
      • Pfizer Investigational Site
  • British Columbia
    • Kelowna, British Columbia, Canada, V1Y 5L3
      • Pfizer Investigational Site
    • Vancouver, British Columbia, Canada, V5Z 4E6
      • Pfizer Investigational Site
    • Victoria, British Columbia, Canada, V8R 6V5
      • Pfizer Investigational Site
  • Manitoba
    • Winnipeg, Manitoba, Canada, R3E 0V9
      • Pfizer Investigational Site
    • Winnnipeg, Manitoba, Canada, R2H 2A6
      • Pfizer Investigational Site
  • Newfoundland and Labrador
    • St. John's, Newfoundland and Labrador, Canada, A1B 3V6
      • Pfizer Investigational Site
  • Nova Scotia
    • Halifax, Nova Scotia, Canada, B3H 1V7
      • Pfizer Investigational Site
    • Halifax, Nova Scotia, Canada, B3H 2Y9
      • Pfizer Investigational Site
  • Ontario
    • London, Ontario, Canada, N6A 4L6
      • Pfizer Investigational Site
    • Toronto, Ontario, Canada, M4N 3M5
      • Pfizer Investigational Site
    • Toronto, Ontario, Canada, M5G 2M9
      • Pfizer Investigational Site
  • Quebec
    • Montreal, Quebec, Canada, H3T 1E2
      • Pfizer Investigational Site
    • Montreal, Quebec, Canada, H2L 4M1
      • Pfizer Investigational Site
• Chile
  • RM
    • Santiago, RM, Chile
      • Pfizer Investigational Site
• Colombia
  • Cali, Colombia
    • Pfizer Investigational Site
  • Cundinamarca
    • Bogotá, Cundinamarca, Colombia, 0000
      • Pfizer Investigational Site
• Croatia
  • Rijeka, Croatia, 51000
    • Pfizer Investigational Site
  • Split, Croatia, 21000
    • Pfizer Investigational Site
• Czech Republic
  • Brno, Czech Republic, 656 53
    • Pfizer Investigational Site
  • Hradec Kralove, Czech Republic, 500 05
    • Pfizer Investigational Site
  • Praha 5, Czech Republic, 150 06
    • Pfizer Investigational Site
  • Praha 8, Czech Republic, 180 00
    • Pfizer Investigational Site
• Ecuador
  • Guayas
    • Guayaquil, Guayas, Ecuador
      • Pfizer Investigational Site
  • Pichincha
    • Quito, Pichincha, Ecuador
      • Pfizer Investigational Site
• Egypt
  • Cairo, Egypt
    • Pfizer Investigational Site
  • Giza, Egypt
    • Pfizer Investigational Site
• Finland
  • Turku, Finland, 20521
    • Pfizer Investigational Site
• France
  • Bordeaux, France, 33000
    • Pfizer Investigational Site
  • Clermont Ferand, France, 63011
    • Pfizer Investigational Site
  • Marseille, France, 13385
    • Pfizer Investigational Site
  • Marseille Cedex 9, France, 13273
    • Pfizer Investigational Site
  • Montpellier, France, 34298 cedex 05
    • Pfizer Investigational Site
  • Paris, France, 75908
    • Pfizer Investigational Site
  • Paris Cedex 13, France, 75651
    • Pfizer Investigational Site
  • Reims, France, 51100
    • Pfizer Investigational Site
  • Rennes, France, 35042
    • Pfizer Investigational Site
  • Tours, France, 37044
    • Pfizer Investigational Site
  • Vandoeuvre les Nancy, France, 54511
    • Pfizer Investigational Site
  • Cedex
    • Saint Herblain, Cedex, France, 44805
      • Pfizer Investigational Site
    • Strasbourg, Cedex, France, 67091
      • Pfizer Investigational Site
  • Cedex 08
    • Lyon, Cedex 08, France, 69008
      • Pfizer Investigational Site
• Germany
  • Aachen, Germany, 52074
    • Pfizer Investigational Site
  • Berlin, Germany, 10117
    • Pfizer Investigational Site
  • Dresden, Germany, 01307
    • Pfizer Investigational Site
  • Essen, Germany, 45122
    • Pfizer Investigational Site
  • Frankfurt, Germany, 60590
    • Pfizer Investigational Site
  • Freiburg, Germany, 79106
    • Pfizer Investigational Site
  • Hamburg, Germany, 20246
    • Pfizer Investigational Site
  • Hannover, Germany, 30625
    • Pfizer Investigational Site
  • Homburg/Saar, Germany, 66421
    • Pfizer Investigational Site
  • Jena, Germany, 07740
    • Pfizer Investigational Site
  • Kassel, Germany, 34125
    • Pfizer Investigational Site
  • Muenchen, Germany, 81664
    • Pfizer Investigational Site
  • Nuernberg, Germany, 90419
    • Pfizer Investigational Site
  • Rostock, Germany, 18057
    • Pfizer Investigational Site
  • Ulm, Germany, 89081
    • Pfizer Investigational Site
• Greece
  • Athens, Greece, 11528
    • Pfizer Investigational Site
  • Patras, Greece, 26500
    • Pfizer Investigational Site
  • Thessaloniki, Greece, 540 07
    • Pfizer Investigational Site
  • Attiki
    • Athens, Attiki, Greece, 115 22
      • Pfizer Investigational Site
• Hong Kong
  • Hong Hong, Hong Kong
    • Pfizer Investigational Site
• Hungary
  • Budapest, Hungary, 1122
    • Pfizer Investigational Site
• India
  • New Delhi, India, 110 085
    • Pfizer Investigational Site
  • Delhi
    • New Delhi, Delhi, India, 110 029
      • Pfizer Investigational Site
  • Maharashtra
    • Pune, Maharashtra, India, 411 004
      • Pfizer Investigational Site
  • Mumbai
    • Parel, Mumbai, India, 400 012
      • Pfizer Investigational Site
  • Rajasthan
    • Jaipur, Rajasthan, India, 302 004
      • Pfizer Investigational Site
• Ireland
  • Dublin, Ireland
    • Pfizer Investigational Site
  • Dublin 24, Ireland
    • Pfizer Investigational Site
• Israel
  • Jerusalem, Israel
    • Pfizer Investigational Site
  • Tel Hashomer, Israel, 52621
    • Pfizer Investigational Site
• Italy
  • Bergamo, Italy, 24128
    • Pfizer Investigational Site
  • Brescia, Italy, 25123
    • Pfizer Investigational Site
  • Cattolica (RN), Italy, 47841
    • Pfizer Investigational Site
  • Cuneo, Italy, 12100
    • Pfizer Investigational Site
  • Legnago, VR, Italy, 37045
    • Pfizer Investigational Site
  • Modena, Italy, 41100
    • Pfizer Investigational Site
  • Napoli, Italy, 80131
    • Pfizer Investigational Site
  • Padova, Italy, 35128
    • Pfizer Investigational Site
  • Parma, Italy, 43100
    • Pfizer Investigational Site
  • Pavia, Italy, 27100
    • Pfizer Investigational Site
  • Perugia, Italy, 06132
    • Pfizer Investigational Site
  • Pordenone, Italy, 33170
    • Pfizer Investigational Site
  • Rimini, Italy, 47900
    • Pfizer Investigational Site
  • Roma, Italy, 00144
    • Pfizer Investigational Site
  • Roma, Italy, 00152
    • Pfizer Investigational Site
  • Roma, Italy, 00135
    • Pfizer Investigational Site
  • Torino, Italy, 10126
    • Pfizer Investigational Site
• Korea, Republic of
  • Seoul, Korea, Republic of, 110-744
    • Pfizer Investigational Site
  • Seoul, Korea, Republic of, 120-753
    • Pfizer Investigational Site
• Lebanon
  • Beirut, Lebanon
    • Pfizer Investigational Site
• Malaysia
  • Kuala Lumpur, Malaysia, 59100
    • Pfizer Investigational Site
  • Selangor
    • Petaling Jaya, Selangor, Malaysia, 46050
      • Pfizer Investigational Site
• Mexico
  • Chihuahua, Mexico, 31000
    • Pfizer Investigational Site
  • Puebla, Mexico, 72530
    • Pfizer Investigational Site
  • DF
    • Mexico, DF, Mexico, 14000
      • Pfizer Investigational Site
    • Mexico, DF, Mexico, 06720
      • Pfizer Investigational Site
  • Estado de Mexico
    • Toluca, Estado de Mexico, Mexico, 50180
      • Pfizer Investigational Site
  • Jalisco
    • Guadalajara, Jalisco, Mexico, 44240
      • Pfizer Investigational Site
  • Yucatan
    • Merida, Yucatan, Mexico, 97000
      • Pfizer Investigational Site
• Netherlands
  • Amsterdam, Netherlands, 1081 HV
    • Pfizer Investigational Site
  • Rotterdam, Netherlands, 3075 EA
    • Pfizer Investigational Site
  • GR
    • Groningen, GR, Netherlands, 9713 GZ
      • Pfizer Investigational Site
  • NH
    • Amsterdam, NH, Netherlands, 1066 CX
      • Pfizer Investigational Site
• Norway
  • Oslo, Norway, 0310
    • Pfizer Investigational Site
• Panama
  • Ciudad de Panama, Panama
    • Pfizer Investigational Site
  • Panama, Panama
    • Pfizer Investigational Site
• Peru
  • Lima, Peru, 11
    • Pfizer Investigational Site
  • Lima, Peru, L13
    • Pfizer Investigational Site
• Philippines
  • Quezon City, Philippines, 1102
    • Pfizer Investigational Site
  • Quezon City, Philippines
    • Pfizer Investigational Site
• Poland
  • Gdansk, Poland, 80-210
    • Pfizer Investigational Site
  • Lodz, Poland, 93-509
    • Pfizer Investigational Site
  • Poznan, Poland, 60-569
    • Pfizer Investigational Site
  • Warszawa, Poland, 00-909
    • Pfizer Investigational Site
  • Wroclaw, Poland, 50-556
    • Pfizer Investigational Site
• Portugal
  • Lisboa, Portugal, 1070-213
    • Pfizer Investigational Site
  • Porto, Portugal, 4200-319
    • Pfizer Investigational Site
• Romania
  • Bucuresti, Romania, 022328
    • Pfizer Investigational Site
  • Cluj-Napoca, Romania, 400015
    • Pfizer Investigational Site
• Russian Federation
  • Chelyabinsk, Russian Federation, 454087
    • Pfizer Investigational Site
  • Moscow, Russian Federation, 115478
    • Pfizer Investigational Site
  • Kaluga region
    • Obninsk, Kaluga region, Russian Federation, 249036
      • Pfizer Investigational Site
• Serbia
  • Belgrade, Serbia, 11000
    • Pfizer Investigational Site
• Singapore
  • Singapore, Singapore, 169610
    • Pfizer Investigational Site
• Slovakia
  • Bratislava, Slovakia, 83301
    • Pfizer Investigational Site
  • Zilina, Slovakia, 012 07
    • Pfizer Investigational Site
• Slovenia
  • Ljubljana, Slovenia, 1000 Ljubljana
    • Pfizer Investigational Site
• Spain
  • Barcelona, Spain, 08035
    • Pfizer Investigational Site
  • Barcelona, Spain, 08025
    • Pfizer Investigational Site
  • La Coruña, Spain, 15006
    • Pfizer Investigational Site
  • Madrid, Spain, 28007
    • Pfizer Investigational Site
  • Madrid, Spain, 28041
    • Pfizer Investigational Site
  • Madrid, Spain, 28040
    • Pfizer Investigational Site
  • Salamanca, Spain, 37007
    • Pfizer Investigational Site
  • Sevilla, Spain, 41013
    • Pfizer Investigational Site
  • Valencia, Spain, 46009
    • Pfizer Investigational Site
  • Asturias
    • Oviedo, Asturias, Spain, 33006
      • Pfizer Investigational Site
  • Barcelona
    • L'hospitalet Del Llobregat, Barcelona, Spain, 08907
      • Pfizer Investigational Site
  • Navarra
    • Pamplona, Navarra, Spain, 31008
      • Pfizer Investigational Site
  • Vizcaya
    • Baracaldo, Vizcaya, Spain, 48903
      • Pfizer Investigational Site
• Sweden
  • Göteborg, Sweden, 413 45
    • Pfizer Investigational Site
  • Lund, Sweden, 221 85
    • Pfizer Investigational Site
  • Stockholm, Sweden, 171 76
    • Pfizer Investigational Site
  • Umeå, Sweden, 901 85
    • Pfizer Investigational Site
• Switzerland
  • Basel, Switzerland, CH-4056
    • Pfizer Investigational Site
  • Bellinzona, Switzerland, CH-6500
    • Pfizer Investigational Site
  • Bern, Switzerland, 3010
    • Pfizer Investigational Site
  • Biel, Switzerland, 2500
    • Pfizer Investigational Site
  • CH-4058 Basel, Switzerland
    • Pfizer Investigational Site
  • CH-4101 Bruderholz, Switzerland
    • Pfizer Investigational Site
  • CH-4410 Liesthal, Switzerland
    • Pfizer Investigational Site
  • Chur, Switzerland, CH-7000
    • Pfizer Investigational Site
  • Genève 14, Switzerland, CH-1211
    • Pfizer Investigational Site
• Taiwan
  • Taipei, Taiwan, 100
    • Pfizer Investigational Site
  • Taipei, Taiwan, 112
    • Pfizer Investigational Site
  • Taoyun, Taiwan, 333
    • Pfizer Investigational Site
• Thailand
  • Bangkok, Thailand, 10330
    • Pfizer Investigational Site
  • Bangkok, Thailand, 10700
    • Pfizer Investigational Site
• Turkey
  • Capa
    • Istanbul, Capa, Turkey, 34390
      • Pfizer Investigational Site
  • Cerrahpasa
    • Istanbul, Cerrahpasa, Turkey, 34303
      • Pfizer Investigational Site
• United Kingdom
  • Belfast, United Kingdom, BT9 7AB
    • Pfizer Investigational Site
  • Birmingham, United Kingdom, B15 2TH
    • Pfizer Investigational Site
  • Birmingham, United Kingdom, B15 2TT
    • Pfizer Investigational Site
  • Bristol, United Kingdom, BS2 8ED
    • Pfizer Investigational Site
  • Cottingham, United Kingdom, HU16 5JQ
    • Pfizer Investigational Site
  • Edinburgh, United Kingdom, EH4 2XU
    • Pfizer Investigational Site
  • Guildford, United Kingdom, GU2 5XX
    • Pfizer Investigational Site
  • London, United Kingdom, NW3 2QG
    • Pfizer Investigational Site
  • London, United Kingdom, SW3 6JJ
    • Pfizer Investigational Site
  • London, United Kingdom, EC1A 7BE
    • Pfizer Investigational Site
  • Manchester, United Kingdom, M20 4BX
    • Pfizer Investigational Site
  • Northwood, United Kingdom, HA6 2RN
    • Pfizer Investigational Site
  • Nottingham, United Kingdom, NG5 1PB
    • Pfizer Investigational Site
  • Sheffield, United Kingdom, S10 2SJ
    • Pfizer Investigational Site
  • Southampton, United Kingdom, SO16 6YD
    • Pfizer Investigational Site
  • Swansea, United Kingdom, SA2 8QA
    • Pfizer Investigational Site
  • Cardiff
    • Whitchurch, Cardiff, United Kingdom, CF14 2TL
      • Pfizer Investigational Site
  • Se1 9rt
    • London, Se1 9rt, United Kingdom
      • Pfizer Investigational Site
  • Surrey
    • Sutton, Surrey, United Kingdom, SM2 5PT
      • Pfizer Investigational Site
  • West Yorkshire
    • Leeds, West Yorkshire, United Kingdom, LS9 7TF
      • Pfizer Investigational Site
• United States
  • Arizona
    • Scottsdale, Arizona, United States, 85260
      • Pfizer Investigational Site
  • California
    • San Francisco, California, United States, 94115
      • Pfizer Investigational Site
    • San Francisco, California, United States, 94115-2378
      • Pfizer Investigational Site
  • Colorado
    • Aurora, Colorado, United States, 80040-0510
      • Pfizer Investigational Site
  • Connecticut
    • Norwalk, Connecticut, United States, 06856
      • Pfizer Investigational Site
  • Florida
    • Miami, Florida, United States, 33176
      • Pfizer Investigational Site
    • Ocala, Florida, United States, 34474
      • Pfizer Investigational Site
    • Tampa, Florida, United States, 33612
      • Pfizer Investigational Site
  • Georgia
    • Atlanta, Georgia, United States, 30309
      • Pfizer Investigational Site
  • Illinois
    • Maywood, Illinois, United States, 60153
      • Pfizer Investigational Site
  • Indiana
    • Indianapolis, Indiana, United States, 46260-2082
      • Pfizer Investigational Site
  • Iowa
    • Council Bluffs, Iowa, United States, 51503
      • Pfizer Investigational Site
  • Louisiana
    • Covington, Louisiana, United States, 70433
      • Pfizer Investigational Site
    • Gretna, Louisiana, United States, 70056
      • Pfizer Investigational Site
    • Marrero, Louisiana, United States, 70072
      • Pfizer Investigational Site
    • Metairie, Louisiana, United States, 70006
      • Pfizer Investigational Site
    • Metairie, Louisiana, United States, 70002
      • Pfizer Investigational Site
    • New Orleans, Louisiana, United States, 70115
      • Pfizer Investigational Site
  • Maryland
    • Baltimore, Maryland, United States, 21287
      • Pfizer Investigational Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Pfizer Investigational Site
    • Boston, Massachusetts, United States, 02115
      • Pfizer Investigational Site
    • Boston, Massachusetts, United States, 02215
      • Pfizer Investigational Site
  • Michigan
    • Detroit, Michigan, United States, 48201
      • Pfizer Investigational Site
  • Minnesota
    • Minneapolis, Minnesota, United States, 55455
      • Pfizer Investigational Site
  • Mississippi
    • Southaven, Mississippi, United States, 38671
      • Pfizer Investigational Site
    • Tupelo, Mississippi, United States, 38801
      • Pfizer Investigational Site
  • Missouri
    • Columbia, Missouri, United States, 65201
      • Pfizer Investigational Site
    • Columbia, Missouri, United States, 65203
      • Pfizer Investigational Site
  • Nebraska
    • Omaha, Nebraska, United States, 68198-7680
      • Pfizer Investigational Site
  • New York
    • Bronx, New York, United States, 10466
      • Pfizer Investigational Site
    • New York, New York, United States, 10021
      • Pfizer Investigational Site
    • New York, New York, United States, 10022
      • Pfizer Investigational Site
  • North Carolina
    • Durham, North Carolina, United States, 27710
      • Pfizer Investigational Site
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • Pfizer Investigational Site
  • Oklahoma
    • Norman, Oklahoma, United States, 73071
      • Pfizer Investigational Site
    • Oklahoma City, Oklahoma, United States, 73112
      • Pfizer Investigational Site
    • Oklahoma City, Oklahoma, United States, 73120
      • Pfizer Investigational Site
    • Oklahoma City, Oklahoma, United States, 73102
      • Pfizer Investigational Site
    • Oklahoma City, Oklahoma, United States, 73109
      • Pfizer Investigational Site
    • Tulsa, Oklahoma, United States, 74104
      • Pfizer Investigational Site
    • Tulsa, Oklahoma, United States, 74136-1902
      • Pfizer Investigational Site
  • Oregon
    • Portland, Oregon, United States, 97210
      • Pfizer Investigational Site
    • Portland, Oregon, United States, 97227
      • Pfizer Investigational Site
  • Pennsylvania
    • Hershey, Pennsylvania, United States, 17033-0850
      • Pfizer Investigational Site
  • Tennessee
    • Memphis, Tennessee, United States, 38104
      • Pfizer Investigational Site
    • Memphis, Tennessee, United States, 38120
      • Pfizer Investigational Site
  • Texas
    • Dallas, Texas, United States, 75246
      • Pfizer Investigational Site
  • Utah
    • Salt Lake City, Utah, United States, 84112
      • Pfizer Investigational Site
  • Washington
    • Seattle, Washington, United States, 98104
      • Pfizer Investigational Site
    • Seattle, Washington, United States, 98122
      • Pfizer Investigational Site
    • Seattle, Washington, United States, 98109
      • Pfizer Investigational Site
    • Seattle, Washington, United States, 98124
      • Pfizer Investigational Site
  • Wisconsin
    • Madison, Wisconsin, United States, 53792
      • Pfizer Investigational Site
• Venezuela
  • Distrito Capital
    • Caracas, Distrito Capital, Venezuela, 1040
      • Pfizer Investigational Site
  • Estado Miranda
    • Caracas, Estado Miranda, Venezuela, 1060
      • Pfizer Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• renal cell carcinoma that is not amendable to standard therapy with curative intent

Exclusion Criteria:

• current treatment in another therapeutic clinical trial

Study Plan

How is the study designed?

Collaborators and Investigators

• Sponsor: Pfizer

Publications and helpful links

General Publications

• Barrios CH, Herchenhorn D, Chacon M, Cabrera-Galeana P, Sajben P, Zhang K. Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma. Onco Targets Ther. 2016 Sep 23;9:5839-5845. doi: 10.2147/OTT.S109445. eCollection 2016.
• Lee SH, Bang YJ, Mainwaring P, Ng C, Chang JW, Kwong P, Li RK, Sriuranpong V, Toh CK, Yuan J, Pitman Lowenthal S, Chung HC. Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy. Asia Pac J Clin Oncol. 2014 Sep;10(3):237-45. doi: 10.1111/ajco.12163. Epub 2014 Feb 27.
• Gore ME, Hariharan S, Porta C, Bracarda S, Hawkins R, Bjarnason GA, Oudard S, Lee SH, Carteni G, Nieto A, Yuan J, Szczylik C. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer. 2011 Feb 1;117(3):501-9. doi: 10.1002/cncr.25452. Epub 2010 Sep 22.
• Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schoffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009 Aug;10(8):757-63. doi: 10.1016/S1470-2045(09)70162-7. Epub 2009 Jul 15.

Helpful Links

• To obtain contact information for a study center near you, click here.

Study record dates

Study Major Dates

• Study Start: July 1, 2005
• Primary Completion (Actual): November 1, 2011
• Study Completion (Actual): November 1, 2011

Study Registration Dates

• First Submitted: August 14, 2005
• First Submitted That Met QC Criteria: August 15, 2005
• First Posted (Estimate): August 16, 2005

Study Record Updates

• Last Update Posted (Estimate): March 9, 2012
• Last Update Submitted That Met QC Criteria: March 8, 2012
• Last Verified: March 1, 2012

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Kidney Neoplasms; Carcinoma, Renal Cell; Carcinoma; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Protein Kinase Inhibitors; Sunitinib
• Other Study ID Numbers: A6181037